James Abbruzzese, MD

Professor of Medicine
D. C. I. Professor of Medical Oncology
Chief, Division of Medical Oncology
Member of the Duke Cancer Institute
Campus mail 440 Mudd Building, Box 3406, Durham, NC 27710
Email address james.abbruzzese@duke.edu

My research interests include the clinical study and treatment of pancreatic cancer.

In Their Words

Education and Training

  • Resident, Internal Medicine, Johns Hopkins University School of Medicine, 1979 - 1981
  • Intern, Internal Medicine, Johns Hopkins University School of Medicine, 1978 - 1979
  • M.D., University of Chicago, 1978

Publications

Bar-Eli, M., J. L. Abbruzzese, D. Lee-Jackson, and P. Frost. “p53 Gene mutation spectrum in human unknown primary tumors.” Anticancer Research 13, no. 5 A (1993): 1619–23.

Scholars@Duke

Hubbard, K. P., R. Pazdur, J. A. Ajani, E. Braud, A. Blaustein, M. King, M. Llenado-Lee, R. Winn, B. Levin, and J. L. Abbruzzese. “Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer..” Am J Clin Oncol 15, no. 6 (December 1992): 524–27.

PMID
1449117
Scholars@Duke

Moore, D. F., R. Pazdur, K. Daugherty, P. Tarassoff, and J. L. Abbruzzese. “Phase II study of gemcitabine in advanced colorectal adenocarcinoma..” Invest New Drugs 10, no. 4 (November 1992): 323–25.

PMID
1487408
Scholars@Duke

Pazdur, R., J. J. Ajani, J. L. Abbruzzese, R. J. Belt, S. R. Dakhil, D. Dubovsky, S. Graham, S. Pilat, R. Winn, and B. Levin. “Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma..” Cancer 70, no. 8 (October 15, 1992): 2073–76. https://doi.org/10.1002/1097-0142(19921015)70:8<2073::aid-cncr2820700810>3.0.co;2-a.

PMID
1394037
Full Text

Jones, D. V., J. A. Ajani, R. Blackburn, K. Daugherty, B. Levin, Y. Z. Patt, and J. L. Abbruzzese. “Phase II study of didemnin B in advanced colorectal cancer..” Invest New Drugs 10, no. 3 (August 1992): 211–13.

PMID
1428730
Scholars@Duke

Anzai, H., P. Frost, and J. L. Abbruzzese. “Synergistic cytotoxicity with 2'-deoxy-5-azacytidine and topotecan in vitro and in vivo..” Cancer Res 52, no. 8 (April 15, 1992): 2180–85.

PMID
1373105
Scholars@Duke

Hubbard, K. P., K. Daugherty, J. A. Ajani, R. Pazdur, B. Levin, and J. L. Abbruzzese. “Phase II trial of fazarabine in advanced colorectal carcinoma..” Invest New Drugs 10, no. 1 (April 1992): 39–42.

PMID
1376722
Scholars@Duke

Meyers, C. A., and J. L. Abbruzzese. “Cognitive functioning in cancer patients: effect of previous treatment..” Neurology 42, no. 2 (February 1992): 434–36. https://doi.org/10.1212/wnl.42.2.434.

PMID
1736178
Full Text

Raber, M. N., J. L. Abbruzzese, and P. Frost. “Unknown primary tumors..” Curr Opin Oncol 4, no. 1 (February 1992): 3–9.

PMID
1591292
Scholars@Duke

Abbruzzese, J. L., and P. Frost. “Studies on the mechanism of the synergistic interaction between 2'-deoxy-5-azacytidine and cisplatin..” Cancer Chemother Pharmacol 30, no. 1 (1992): 31–36.

PMID
1375133
Scholars@Duke

Pages